Nxera Pharma Co Ltd (4565)

Tokyo
Currency in JPY
931.0
-39.0(-4.02%)
Closed
4565 Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
Trading near 52-week Low
Fair Value
Day's Range
927.0969.0
52 wk Range
927.01,826.0
Key Statistics
Edit
Bid/Ask
931.00 / 933.00
Prev. Close
970
Open
968
Day's Range
927-969
52 wk Range
927-1,826
Volume
1.02M
Average Volume (3m)
639.47K
1-Year Change
-38.09%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4565 Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
2,040.0
Upside
+119.12%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Nxera Pharma Co Ltd Company Profile

Nxera Pharma Co., Ltd. develops and sells biopharmaceutical products in Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its product portfolio products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair and Breezhaler for the treatment of asthma; ORAVI, a novel formulation for the treatment of oropharyngeal candidiasis; and PIVLAZ for the treatment of cerebral vasospasm indications. The company’s development products pipeline consists of HTL0039732 for immuno-oncology indications; HTL0048149 for schizophrenia disorders; Daridorexant for the treatment of insomnia; HTL0016878 for schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; PF-06954522 for metabolic diseases; NBI-1117569 for neurology diseases; and NBI-1117570 for central nervous system (CNS) disorders. It is also involved in the development of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; and other discovery and preclinical stage drugs. Nxera Pharma Co., Ltd. has a strategic collaboration with AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily; and strategic research and development partnership with PrecisionLife to auto-immune disorders with the potential to identify new drug targets for the treatment of chronic conditions. Nxera Pharma Co., Ltd. was incorporated in 1990 and is headquartered in Tokyo, Japan.

Employees
360
Market
Japan

Compare 4565 to Peers and Sector

Metrics to compare
4565
Peers
Sector
Relationship
P/E Ratio
−22.6x8.9x−0.6x
PEG Ratio
10.340.010.00
Price/Book
1.2x1.1x2.6x
Price / LTM Sales
2.9x1.9x3.1x
Upside (Analyst Target)
85.6%4.7%55.2%
Fair Value Upside
Unlock18.7%9.8%Unlock

Analyst Ratings

9 Buy
1 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 2,040.0

(+119.12% Upside)

Earnings

Latest Release
Nov 1, 2024
EPS / Forecast
13.45 / 0.2816
Revenue / Forecast
9.26B / 12.56B
EPS Revisions
Last 90 days

FAQ

What Is the Nxera Pharma (4565) Stock Price Today?

The Nxera Pharma stock price today is 931.00

What Stock Exchange Does Nxera Pharma Trade On?

Nxera Pharma is listed and trades on the Tokyo stock exchange.

What Is the Stock Symbol for Nxera Pharma?

The stock symbol for Nxera Pharma is "4565."

What Is the Nxera Pharma Market Cap?

As of today, Nxera Pharma market cap is 83.70B.

What is Nxera Pharma Earnings Per Share?

The Nxera Pharma EPS is -42.09.

What Is the Next Nxera Pharma Earnings Date?

Nxera Pharma will release its next earnings report on 17 Feb 2025.

From a Technical Analysis Perspective, Is 4565 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.